Orion Oyj (0M2O.IL)

35,87 0,00 (0,00%) Alla chiusura: 09:13AM BST

Orion Oyj

Orionintie 1A
Espoo 02200
Finland
358 10 4261
https://www.orion.fi

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 3.657

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Liisa Hurme	Pres, CEO & Chairman of Exec. Management Board	106,13k	N/D	1967
Mr. Jari Karlson M.Sc., M.Sc. (Econ.)	CFO & Member of the Exec. Management Board	N/D	N/D	1961
Mr. Olli Huotari Ll.M.	Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board	N/D	N/D	1966
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.)	Sr. VP of Generics and Consumer Health Bus. Division & Member of the Exe. Mgmt. Board	N/D	N/D	1966
Ms. Virve Laitinen M.Sc. (Tech.), MBA	Sr. VP of Corp. Strategy and Program Mgmt. Grp. Level Function & Member of the Exe. Mgmt. Board	N/D	N/D	1972
Prof. Outi Vaarala M.D., Ph.D.	Sr. VP of Innovative Medicines, Sr. VP of R&D and Member of the Exe. Mgmt. Board	N/D	N/D	1962
Mr. Juhani Kankaanpaa	Sr. VP of Global Operations & Member of Exec. Management Board	N/D	N/D	N/D
Mr. Niclas Lindstedt EMBA, M.Sc.	Sr. VP of Animal Health Bus. Division & Member of the Exe. Mgmt. Board	N/D	N/D	N/D
Mr. Hao Pan M.Sc.	Sr. VP of the Branded Products Bus. Division & Member of the Exe. Mgmt. Board	N/D	N/D	1971
Mr. Tuukka Hirvonen M.Sc.(Soc.)	Investor Relations & Financial Communications Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Precedex for intensive care sedative, as well as Fareston for breast cancer. The company also offers Salmeterol/fluticasone Easyhaler; Budesonide/formoterol Easyhaler; Formoterol Easyhaler; Budesonide Easyhaler; Beclomet Easyhaler; and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic and proprietary drugs, as well as provides contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. The company serves primarily healthcare services providers and professional, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Further, it has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. The company was founded in 1917 and is headquartered in Espoo, Finland.

Governance aziendale

L'ISS Governance QualityScore di Orion Oyj al 1 ottobre 2023 è 3. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 2; diritti degli azionisti: 10; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.